Clinical trials: sponsored by Verastem, Inc.
Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1…
- Trial name
- NCT03727880
- Testing
- Pembrolizumab, Defactinib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Lei Zheng
Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma)
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of avutometinib and defactinib and to determine the preliminary antitumour activity of avutometinib and defactinib administered at the recommended…
- Conditions
- Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary Gliomas
- Trial name
- 5G-RUBY (NCT06630260)
- Testing
- Avutometinib, Defactinib, Temozolomide
- Where
- 3 sites in United Kingdom
- Volunteers
- 182 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Non Small Cell Lung Cancer, KRAS Activating Mutation
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to…
- Trial name
- RAMP203 (NCT05074810)
- Testing
- avutometinib and sotorasib, avutometinib and sotorasib and defactinib
- Where
- 35 sites in United States, Belgium and 4 more
- Volunteers
- 153 people
- Sponsor
- Verastem, Inc.
Low Grade Serous Ovarian Cancer, Ovarian Cancer
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
This study will confirm the safety and efficacy of avutometinib in combination with defactinib in Japanese patients with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
- Trial name
- RAMP201J (NCT06682572)
- Testing
- Avutometinib (VS-6766) + Defactinib (VS-6063)
- Where
- 5 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Verastem, Inc.
Glioblastoma, Recurrent Glioblastoma
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
This early phase I trial tests brain concentration level and safety of defactinib or VS-6766 for the treatment of patients with glioblastoma.
- Trial name
- NCT05798507
- Testing
- Avutometinib, Biospecimen Collection, Defactinib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Emory University
Cutaneous Melanoma, Brain Metastases
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
The goal of this interventional clinical trial is to provide proof-of-principle data for the biologic activity of defactinib in combination with avutometinib in brain metastases from melanoma, and to define the potential role of…
- Trial name
- DETERMINE (NCT06194929)
- Testing
- Defactinib, Avutometinib, Encorafenib
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Utah
Endometrioid Cancer, Mucinous Ovarian Cancer
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian…
- Conditions
- Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer, Cervical Cancer
- Trial name
- DURAFAK (NCT05512208)
- Testing
- Avutometinib (VS-6766) + defactinib
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Oklahoma
KRAS Activating Mutation, Metastatic Cancer
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously…
- Conditions
- KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic
- Trial name
- RAMP205 (NCT05669482)
- Testing
- avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Verastem, Inc.
Metastatic Uveal Melanoma
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
This phase II trial studies the effect of combining defactinib and VS-6766 in treating patients with uveal melanoma that has spread to other places in the body (metastatic).
- Trial name
- NCT04720417
- Testing
- Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766, Biopsy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Thomas Jefferson University
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
- Trial name
- RAMP 201 (NCT04625270)
- Testing
- avutometinib (VS-6766), avutometinib (VS-6766) and defactinib
- Where
- 47 sites in United States, Belgium and 5 more
- Volunteers
- 225 people
- Sponsor
- Verastem, Inc.
Malignant Pleural Mesothelioma
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
This is an open label neoadjuvant (treatment with VS-6063 prior to mesothelioma surgery) study in subjects with malignant pleural mesothelioma who are eligible for surgery.
- Trial name
- NCT02004028
- Testing
- VS-6063
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Verastem, Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.
- Trial name
- RAMP202 (NCT04620330)
- Testing
- avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib
- Where
- 45 sites in United States, France and 3 more
- Volunteers
- 90 people
- Sponsor
- Verastem, Inc.
COVID-19
Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)
In this study, patients with severe coronavirus disease 2019 (COVID-19) infection will be randomized to receive duvelisib or a placebo.
- Trial name
- DAMPEN-CI (NCT04487886)
- Testing
- Duvelisib
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Emory University
COVID-19
Duvelisib to Combat COVID-19
The exceedingly high mortality rates of severe and critical COVID-19 warrant the identification and evaluation of novel therapies that could potentially mitigate the advanced disease manifestations.
- Trial name
- NCT04372602
- Testing
- Duvelisib, Peripheral blood draw
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Washington University School of Medicine
Food Effect
Food Effect of VS-6766 in Healthy Adult Subjects
An Open-Label, 2-Way, 2-Period Crossover Study of Orally Administered VS-6766 in Healthy Adult Subjects to Determine the Effect of Food on the Pharmacokinetics of VS-6766
- Trial name
- NCT05187169
- Testing
- VS-6766
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Verastem, Inc.
Advanced Solid Tumors, Solid Tumors
Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
In pancreatic cancer, targeting the tumor microenvironment has become a promising therapeutic strategy. Focal adhesion kinase (FAK) pathway activation is essential for promoting a fibrotic and inflammatory tumor microenvironment…
- Conditions
- Advanced Solid Tumors, Solid Tumors, Pancreatic Cancer
- Trial name
- NCT02546531
- Testing
- Defactinib, Pembrolizumab, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Washington University School of Medicine
Epithelial Ovarian Cancer
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
This is a Phase 1/1b, open-label, multicenter, dose-escalation and dose expansion trial to evaluate the safety, efficacy, PK and PD of defactinib (VS-6063) in combination with avelumab in epithelial ovarian cancer.
- Trial name
- NCT02943317
- Testing
- Part A - VS-6063, Part A - Avelumab
- Where
- 5 sites in United States
- Volunteers
- 98 people
- Sponsor
- Verastem, Inc.
Carcinoma, Non-small-cell Lung, Mesothelioma
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
This study will explore whether defactinib (a FAK inhibitor) can be safely and tolerably combined with pembrolizumab (a PD-1 inhibitor) and will look for early indications of improved anticancer immunotherapy.
- Conditions
- Carcinoma, Non-small-cell Lung, Mesothelioma, Pancreatic Neoplasms
- Trial name
- NCT02758587
- Testing
- Defactinib, Pembrolizumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 59 people
- Sponsor
- NHS Greater Glasgow and Clyde
Non Hematologic Cancers, Metastatic Cancer
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
This is a Phase I, open-label, multicenter, dose-escalation trial of VS-4718, a focal adhesion kinase inhibitor, in subjects with metastatic non-hematologic malignancies.
- Trial name
- NCT01849744
- Testing
- VS-4718
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Verastem, Inc.
Pancreatic Cancer
Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects
The purpose of this study is to evaluate increasing dose levels of VS-4718 administered in combination with gemcitabine and nab-paclitaxel in subjects with advanced cancer and to determine a recommended Phase 2 dose (RP2D) for…
- Trial name
- NCT02651727
- Testing
- Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine, Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine, Part A- VS-4718, nab-paclitaxel, gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Verastem, Inc.